Safety of Different Weight-Based Dosing Strategies of Intravenous Acyclovir in Obese Patients: A Retrospective Cohort Study

被引：0
作者：
Saad, Mohamed Omar [1 ]
Habib, Safeya Omar [2 ]
Alhomosy, Ahmed Mohammed [1 ]
Salem, Islam Mohamed [1 ]
Hishari, Ola Mohamad [1 ]
机构：
[1] Hamad Med Corp, Al Wakra Hosp, Pharm Dept, Doha, Qatar
[2] Qatar Univ, Coll Pharm, POB 2713, Doha, Qatar
来源：
ANNALS OF PHARMACOTHERAPY | 2025年
关键词：
acyclovir; obesity; ideal; adjusted; body weight; nephrotoxicity; acute kidney injury; INDUCED RENAL-FAILURE; PHARMACOKINETICS;
D O I：
10.1177/10600280251318017
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Background: In obese patients receiving intravenous (IV) acyclovir, conflicting data exist regarding the risk of acute kidney injury (AKI) with different weight-based dosing strategies: total body weight (TBW), adjusted body weight (AdjBW), and ideal body weight (IBW).Objective: We aimed to compare the safety of the 3 dosing strategies in obese patients.Methods: A retrospective cohort study including obese patients who received IV acyclovir during their inpatient admissions. Patients were categorized into TBW, AdjBW, or IBW groups based on the received doses. The primary outcome was the incidence of AKI. Other outcomes included the need for renal replacement therapy (RRT), neurotoxicity, length of stay (LOS), and in-hospital mortality.Results: A total of 339 patients were included: 196 patients in TBW group, 86 patients in AdjBW group, and 57 patients in IBW group. The AKI developed in 17.3%, 11.6%, and 7% of TBW, AdjBW and IBW groups, respectively. After adjustment for confounders, reduced dosing (AdjBW or IBW) was associated with fewer AKI compared with TBW dosing (adjusted odds ratio (aOR) [95% CI] = 0.39 [0.19, 0.82]). Compared with TBW, IBW was associated with fewer AKI (aOR [95% CI] = 0.27 [0.08, 0.85]), but AdjBW was not (aOR [95% CI] = 0.48 [0.21, 1.09]). Median LOS was numerically longer with IBW but was not significantly different from other groups. The need for RRT, neurotoxicity, and mortality did not differ between groups.Conclusion and Relevance: In obese patients, either AdjBW or IBW dosing of IV acyclovir appears to be safer than TBW. The IBW dosing had the lowest odds of AKI among the 3 dosing strategies.
引用
收藏
页数：8
相关论文
共 25 条
  • [1] Package insert. Fresenius Kabi USA, LLC
  • [2] Perazella M.A., Crystal-induced acute renal failure, Am J Med, 106, 4, pp. 459-465, (1999)
  • [3] Sawyer M.H., Webb D.E., Balow J.E., Straus S.E., Acyclovir-induced renal failure: clinical course and histology, Am J Med, 84, 6, pp. 1067-1071, (1988)
  • [4] Tucker W.E., Preclinical toxicology profile of acyclovir: an overview, Am J Med, 73, 1, pp. 27-30, (1982)
  • [5] Xing W., Gu L., Zhang X., Xu J., Lu H., A metabolic profiling analysis of the nephrotoxicity of acyclovir in rats using ultra performance liquid chromatography/mass spectrometry, Environ Toxicol Pharmacol, 46, pp. 234-240, (2016)
  • [6] Joannidis M., Druml W., Forni L.G., Et al., Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017, Intensive Care Med, 43, 6, pp. 730-749, (2017)
  • [7] Hellden A., Odar-Cederlof I., Diener P., Et al., High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study, Nephrol Dial Transplant, 18, 6, pp. 1135-1141, (2003)
  • [8] Brandariz-Nunez D., Correas-Sanahuja M., Maya-Gallego S., Martin Herranz I., Neurotoxicity associated with acyclovir and valacyclovir: a systematic review of cases, J Clin Pharm Ther, 46, 4, pp. 918-926, (2021)
  • [9] Hernandez J.O., Norstrom J., Wysock G., Acyclovir-induced renal failure in an obese patient, Am J Health Syst Pharm, 66, 14, pp. 1288-1291, (2009)
  • [10] Seedat A., Winnett G., Acyclovir-induced acute renal failure and the importance of an expanding waist line, Case Rep, 2012, (2012)
123